Joel Isaacson & Co’s GSK GSK Stock Holding History

Joel Isaacson & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$369K	Buy	7,040 +1,582	+29%	+$83.7K	0.01%	347
2026 Q1	$301K	Buy	5,458 +228	+4%	+$12.4K	0.01%	362
2025 Q4	$256K	Buy	5,230 +20	+0.4%	+$933	0.01%	389
2025 Q3	$225K	Buy	+5,210	New	+$204K	0.01%	413
2017 Q1	–	Sell	-1,209	Closed	-$58K	–	318
2016 Q4	$58K	Hold	1,209	–	–	0.01%	284
2016 Q3	$65K	Hold	1,209	–	–	0.01%	289
2016 Q2	$65K	Sell	1,209 -90	-7%	-$4.74K	0.01%	289
2016 Q1	$66K	Hold	1,299	–	–	0.01%	298
2015 Q4	$66K	Sell	1,299 -64	-5%	-$3.26K	0.02%	285
2015 Q3	$66K	Hold	1,363	–	–	0.02%	287
2015 Q2	$71K	Hold	1,363	–	–	0.02%	305
2015 Q1	$79K	Buy	1,363 +1	+0.1%	+$57	0.02%	291
2014 Q4	$73K	Buy	1,362 +107	+9%	+$5.99K	0.02%	270
2014 Q3	$72K	Hold	1,255	–	–	0.02%	250
2014 Q2	$84K	Hold	1,255	–	–	0.03%	228
2014 Q1	$84K	Hold	1,255	–	–	0.03%	223
2013 Q4	$84K	Sell	1,255 -1,680	-57%	-$109K	0.03%	209
2013 Q3	$184K	Hold	2,935	–	–	0.08%	112
2013 Q2	$183K	Buy	+2,935	New	+$186K	0.09%	101

Other funds holding GSK

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EIC

Equity Investment Corp Atlanta, Georgia $5.24B AUM 11.32% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

MHI

Miller Howard Investments Kingston, New York $3.77B AUM 23.82% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Joel Isaacson & Co's GSK Position: Q2 2026 in Review

Joel Isaacson & Co increased its GSK (GSK) stake by 29% in Q2 2026, buying an estimated $83.7K and bringing the position to 7,040 shares worth $369K. The position accounts for 0.01% of the portfolio, ranked #347.

Joel Isaacson & Co first reported a position in GSK in Q2 2013 and has held it in 19 quarters since. 627 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Joel Isaacson & Co held 7,040 shares of GSK worth $369K as of Q2 2026.
Joel Isaacson & Co bought 1,582 GSK shares in Q2 2026, an estimated $83.7K.
GSK made up 0.01% of Joel Isaacson & Co's portfolio in Q2 2026, its #347 holding.
Joel Isaacson & Co first reported a position in GSK in Q2 2013 and has held it in 19 quarters since.
627 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Joel Isaacson & Co's 13F filing for Q2 2026, filed 4 Aug 2026.